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Abstract
An isolate of the methicillin-resistant Staphylococcus aureus (MRSA) clone USA300 with reduced susceptibility to
vancomycin (SG-R) (i.e, vancomycin-intermediate S. aureus, VISA) and its susceptible ‘‘parental’’ strain (SG-S) were recovered
from a patient at the end and at the beginning of an unsuccessful vancomycin therapy. The VISA phenotype was unstable in
vitro generating a susceptible revertant strain (SG-rev). The availability of these 3 isogenic strains allowed us to explore
genetic correlates of antibiotic resistance as it emerged in vivo. Compared to the susceptible isolate, both the VISA and
revertant strains carried the same point mutations in yycH, vraG, yvqF and lspA genes and a substantial deletion within an
intergenic region. The revertant strain carried a single additional frameshift mutation in vraS which is part of two
component regulatory system VraSR. VISA isolate SG-R showed complex alterations in phenotype: decreased susceptibility
to other antibiotics, slow autolysis, abnormal cell division and increased thickness of cell wall. There was also altered
expression of 239 genes including down-regulation of major virulence determinants. All phenotypic properties and gene
expression profile returned to parental levels in the revertant strain. Introduction of wild type yvqF on a multicopy plasmid
into the VISA strain caused loss of resistance along with loss of all the associated phenotypic changes. Introduction of the
wild type vraSR into the revertant strain caused recovery of VISA type resistance. The yvqF/vraSR operon seems to function
as an on/off switch: mutation in yvqF in strain SG-R turns on the vraSR system, which leads to increase in vancomycin
resistance and down-regulation of virulence determinants. Mutation in vraS in the revertant strain turns off this regulatory
system accompanied by loss of resistance and normal expression of virulence genes. Down-regulation of virulence genes
may provide VISA strains with a ‘‘stealth’’ strategy to evade detection by the host immune system.
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Introduction
The extensive use of antibiotics in the clinical environment has
led to the appearance of a wide variety of drug resistance
mechanisms among all bacterial pathogens, including S. aureus.
While most of these resistance mechanisms are associated with the
acquisition of ‘‘foreign’’ genetic elements – others involve a more
direct selection of bacterial mutants that can survive and overcome
the inhibitory effects of the antibiotic. Examples for such adaptive
resistance mechanism are provided by the appearance of S. aureus
strains with decreased susceptibility to the antibiotic vancomycin.
These so-called VISA isolates (for Vancomycin intermediate S.
aureus) were usually recovered from patients with vancomycin
treatment failure (for review see [1]). Although development of
VISA type resistance has been described during vancomycin
treatment of methicillin susceptible S. aureus (MSSA) infections [2],
the vast majority of VISA isolates were identified in MRSA strains,
i.e., multidrug resistant isolates of S. aureus against which the
therapy of choice has been vancomycin for some time. This highly
concentrated selective pressure on MRSA is undoubtedly the
primary reason for the emergence of vancomycin resistant mutants
in the most frequent lineages of these already multiresistant strains.
Thus, isolates exhibiting VISA type resistance have been identified
in strains belonging to most of the major epidemic MRSA clones.
The first VISA isolate – MU50 described in Japan in 1997 [3] and
VISA isolates from New Jersey, Michigan [4] and from
Portchester [5] all share sequence type ST5 of the ‘‘New York/
Japan’’ MRSA clone. Similarly, a series of VISA isolates exhibiting
gradually decreasing levels of susceptibility to vancomycin belong
to ST105 which is a single locus variant of the same ST5 clone [6–
8]. Several VISA isolates were identified in the ST239 Brazilian
MRSA [9] and a recently described VISA isolate – VISA-BRAGA
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– belongs to the EMRSA-15 clone of ST22 [10]. Two most recent
communications described recovery of isolates with VISA type
resistance from infections caused by the USA300 clone belonging
to ST8 [11–12]. The appearance of VISA type resistance in the
genetic background of this highly virulent MRSA lineage –
frequently associated with both community and hospital acquired
infections – is of concern.
An intriguing feature of the VISA phenotype is the large
number of physiological and morphological abnormalities that has
been observed in most if not all of such bacteria. These
abnormalities include changes in morphology, pattern of cell
division, decrease in proneness to autolysis; suppression of
hemolysis, abnormal structure of the cell surface, decreased
virulence in animal models. The multiplicity of these phenotypic
changes suggests that the mechanism of VISA-type vancomycin
resistance involves alteration in (a) genetic determinant(s) that
control such complex phenomena.
In this communication we describe microbiological, transcrip-
tional and genetic analysis of the VISA type resistance to
vancomycin in a clinical isolate belonging to the USA300 MRSA
clone [11]. The results suggest that a mutated yvqF causing over-
expression of the VraSR regulon is the key factor leading to the
increase in the vancomycin MIC value and – more importantly –
to the down-regulation of numerous virulence genes which may
equip the bacteria with a strategy to evade immune surveillance
during invasion and prolong survival in the host and also
contribute to the unique clinical features of VISA type infections.
Results
Multiple and reversible alterations in the phenotype of a
vancomycin resistant (VISA) isolate of the MRSA clone
USA300
Decreased susceptibility to several cell wall
inhibitors. The antibiotic susceptibility profile of the resistant
isolate SG-R (San Francisco General Hospital-Resistant) recovered at
the end of an unsuccessful vancomycin therapy was determined by the
E-test and population analysis profile and was compared to the
corresponding values of the ‘‘parental’’ strain SG-S (San Francisco
General Hospital-Susceptible). The vancomycin MIC of SG-R was
3 mg/ml as compared to the MIC of 1 to 1.5 mg/ml in SG-S
(Figure 1A). Plating the bacterial strains for population analysis
showed that cultures of the resistant isolate SG-Rwere heterogeneous:
the majority of cells could grow at 2 mg/ml with a 3 log10 decrease at
3 mg/ml, but subpopulations with higherMIC values for vancomycin
were also present with low frequencies. In contrast, cultures of the
parental strain SG-S and the revertant SG-rev were more
homogeneous with no growth observable at 2 mg/ml (Figure 1B).
The resistant isolate SG-R also showed modest but significant
increase in the MIC value for oxacillin from 0.5 to 3 mg/ml as
shown by a shift in the population analysis profile– (see Figure 1C).
The resistant isolate SG-R also showed increased MICs for
daptomycin (from 0.25 to 1.5 mg/ml), fosfomycin (from 1.5 to
8 mg/ml) and moenomycin (from 0.6 to 1.25 mg/ml) (Table 1).
There was no difference detectable between strains SG-R and SG-
S in susceptibility to levofloxacin, rifampin, chloramphenicol,
tetracycline and mupirocin (data not shown) and the three strains
were equally susceptible to linezolid and tigecycline – two
antibiotics frequently used in the therapeutic setting.
In the isolate SG-rev (San Francisco General Hospital-
revertant) that lost resistance to vancomycin during in vitro passage,
the MIC values for various cell wall inhibitors were similar to or
lower than the MICs for the ‘‘parental’’ strain (see Table 1).
PFGE of SmaI digested DNA confirmed that the three strains
SG-S, SG-R and SG-rev had identical band patterns (data not
shown).
Defective cell division and abnormal morphology. Isolates
SG-S, SG-R and SG-rev were grown in a nonselective medium
under identical growth conditions and subjected to morphometric
analysis by phase contrast and transmission electron microscopy. In
contrast to the regularly shaped and well separated cells of the
susceptible parental (SG-S) and revertant (SG-rev) cultures, the
resistant strain SG-R grew inmulticellular aggregates (.90% of cells),
showed irregularly spaced and ‘‘thicker’’ than normal septae and cell
walls surrounded by amorphous extracellular material (100% of the
cells) (see figures 2A–C).
Reduced rate of Triton X-100 induced autolysis. Liquid
cultures of strains SG-R, SG-S and the revertant SG-rev grew with
comparable rates in TSB in the logarithmic phase of growth.
However, following back dilution of the overnight cultures, the
resistant strain SG-R showed a considerable lag before resumption
of growth, which occurred with the same rate as the parental and
revertant strain (data not shown). The three strains were subjected
to Triton X-100 stimulated autolysis and decrease in OD620 was
followed every 15 minutes. The rate of autolysis of the resistant
mutant SG-R was slower than that of the susceptible strain SG-S
or the revertant SG-rev (Figure 3).
Peptidoglycan isolated from strains SG-S, SG-R and SG-rev
were analyzed by reverse-phase HPLC. The muropeptide elution
profiles of the three strains were virtually identical with one
exception: the representation of the minor muropeptide compo-
nent 1 – the monomeric disaccharide pentapeptide with no
oligoglycine branches [13] – which was slightly increased in strain
SG-R (data not shown).
Zymographic analyses [8] detected no significant differences
between the autolytic enzyme profiles of the three strains (data not
shown).
Altered gene expression in the vancomycin resistant
isolate SG-R
The transcriptional profile of the resistant isolate SG-R was
compared to that of the susceptible parental strain SG-S and the
Author Summary
The extensive use of antibiotics has led to the selection of
methicillin-resistant S. aureus (MRSA) strains that are
resistant to most antimicrobial agents and a treatment of
choice against such strains is vancomycin. However, during
the last decade reports of treatment failure with vanco-
mycin non-susceptible MRSA (e.g., vancomycin intermedi-
ate S. aureus, VISA) began to appear in the clinical setting.
In this paper we analyze the mechanism of resistance in a
VISA strain that belongs to the epidemic and highly
virulent MRSA clone USA300. We had 3 isogenic isolates
available for analysis: the vancomycin susceptible parental
strain recovered from the patient before the onset of
therapy; the VISA strain recovered at the time of clinical
treatment failure and a susceptible revertant of the VISA
strain acquired during in vitro passage. We identified
genetic differences among the three strains through whole
genome sequencing. In this strain, the key genetic change
responsible for vancomycin resistance was in the func-
tionally connected yvqF/vraSR - two component sensory
regulatory system involved with the control of cell wall
metabolism of the bacteria. The same genetic change also
caused repression of virulence related properties which
may help the resistant bacteria to evade the host immune
system.
Genetic Changes in Vancomycin Resistant S. aureus
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Figure 1. Vancomycin and oxacillin susceptibility profiles of strains SG-S, SG-R and SG-rev. Strains SG-S, SG-R and SG-rev were grown
overnight in TSB and were used to determine vancomycin MIC values using the E-test with bacteria plated on TSA (A). Vancomycin and oxacillin
susceptibility were also determined by population analysis (B) and (C).
doi:10.1371/journal.ppat.1002505.g001
Genetic Changes in Vancomycin Resistant S. aureus
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Table 1. Relevant phenotypic properties of the strains used in this study.
Strain Vana Oxaa, b DPa FMa MOa LZ TGC Autolysis rate Cell Division Thickness of the cell wall
SG-S 1–1.5 0.5 0.25 1.5 0.6 S S Normal Normal Normal
SG-R 3 3 1.5 8 1.25 S S Reduced Defective Thick
SG-rev 0.5–1 0.38 0.19 0.38 0.07 S S Normal Normal Normal
Van – vancomycin; Oxa – oxacillin; DP – daptomycin, FM – fosfomycin, MO – moenomycin, LZ – linezolid, and TGC - tigecycline. (a) MIC values in mg/ml. (b) strain
USA300 is a heterogeneously resistant MRSA strain in which – similarly to other heteroresistant MRSA – the majority of cells expressed only marginal level of resistance
to oxacillin [69]. Complete population analysis profiles of vancomycin and oxacillin resistance for the SG strains are shown in Figs 1 B and C, respectively.
doi:10.1371/journal.ppat.1002505.t001
Figure 2. Phenotypes of strains SG-S, SG-R and SG-rev. Phenotypes of strains SG-S, SG-R and SG-rev were characterized by phase-contrast
microscopy (A), and electron microscopy of thin sections (B & C).
doi:10.1371/journal.ppat.1002505.g002
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revertant mutant SG-rev. Genes that showed a fold change cut off
$2 accompanied by a p-value cut off #0.05 in at least one of the
comparisons were selected for further investigation. All genes with
significant altered expression in the three strains are listed in
Table 2, Table S1 and Figure S1 and are categorized according to
their functional group.
In the VISA strain SG-R 65 genes were up-regulated and 174
genes down-regulated – as compared to the parental strain SG-S
(Tables 2, Table S1 and Figure S1). Out of these differentially
transcribed genes, 20 encode for transport and binding proteins, 17
are linked to ribosomal processes, 16 to pathogenesis, 15 to energy
metabolism, another 15 to cell envelope structure or biosynthesis, 12
to regulatory functions and 7 to central intermediary metabolism
(Table 2). The majority of genes represented in Table S1 and Figure
S1 (a total of 82 genes) are predicted to encode for proteins with
unidentified functions. The altered transcription of a select group of
these genes (lytM, agrA, sgtB, orf2302, prsA, SceD) was confirmed by
Northern blot analysis (data not shown).
In the revertant isolate SG-rev the majority of genes that
showed altered transcription in SG-R have returned to a pattern of
normal transcription seen in the parental strain: only 8 genes with
statistical significance (p#0.05) could still be found differentially
expressed in the comparison between the revertant strain and the
parental strain – and among these genes was vraG (Table S1 and
Figure S1) that is mutated in both SG-R and SG-rev (see Table 3).
Genetic basis of antibiotic resistance
Whole genome sequencing analysis allowed identification of
genetic differences among the three strains. Four nucleotide
substitutions and a significant deletion of an intergenic region
(367 bp) were found in the genome of the resistant isolate SG-R
when compared to that of the parental strain SG-S (see Table 3).
Each of the four mutations located in the yycH [14–15], vraG [16],
yvqF [7,17] and lspA [18] led to non-synonymous amino acid
substitutions – in YycH (from non-polar to polar), in the ABC
transporter permease VraG (from non-polar to polar), in YvqF
(from polar to non-polar), and in LspA (from polar to polar).
Detailed analysis of the deleted intergenic region showed that this
fragment of DNA corresponds to the non-protein-coding
(npc)RNA Sau-02 identified by Abu-Qatouseh et al. in a study
with small colony variants of S. aureus [19].
The revertant strain SG-rev carried the same mutations
identified in SG-R but had an additional genetic alteration: a
single nucleotide deletion in vraS. This mutation caused a
frameshift in vraS and – presumably – a premature termination
(at amino acid 234) of the histidine kinase VraS in the two-
component system VraSR [20–21]. Sequencing confirmed each of
the mutations present in the genomes of SG-R and SG-rev.
Role of yvqF and vraSR in the expression of vancomycin
resistance in strains SG-R and SG-rev
Whole genome sequencing provided evidence that the labora-
tory strain SG-rev may have lost the vancomycin resistant
phenotype due to the deletion of a single nucleotide in the gene
vraS suggesting the production of a ‘‘shortened’’ VraS histidine
kinase. In S. aureus, the two genes yvqF and vraS were shown to
be parts of the same operon [22], but a functional connection
between the two genes was based most often on evidence provided
Figure 3. Triton X-100-stimulated autolysis of the SG-S, SG-R, and SG-rev strains. Cultures were suspended in Triton X-100 autolysis buffer
to an initial OD620 of approximately 1.0, and the rates of autolysis were monitored as decrease of OD620 in time.
doi:10.1371/journal.ppat.1002505.g003
Genetic Changes in Vancomycin Resistant S. aureus
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by homology to determinants in other bacterial species: liaF (ortholog
of yvqF) and liaR (ortholog of vraR) described in B. subtilis. The yvqF
homologue liaF was shown to be a negative regulator of liaR [23].
Homologs of yvqF with similar function were also identified in
Streptococcus mutans [24] and Listeria monocytogenes [25]. Independent
evidence for a direct interaction between YvqF and VraS was
provided by recent studies with the bacterial two-hybrid system [26].
These observations suggested that the mutated yvqF (and not the
other 4 mutations present in SG-R) may represent the key genetic
determinant associated with the acquisition of vancomycin
resistance in strain SG-R. To test this hypothesis complementation
experiments were performed.
Complementation experiments
Abolishment of vancomycin resistance in strain SG-R – by
over-expression of wild-type yvqF. The wild type form of
yvqF linked to the main promoter region of the vraSR operon [22]
was fused to the plasmid pGC2 and introduced into strain SG-R.
Over-expression of pGC2 carrying the wild type form of yvqF gene
in strain SG-R completely abolished the vancomycin resistant
phenotype: MIC was reduced from 3 to 1.5 mg/ml (Figure 4).
The complemented strain also recovered normal cell division,
normal rate of TritonX-100 induced autolysis and low oxacillin
MIC value – all characteristics of the parental strain SG-S (data
not shown).
Recovery of vancomycin resistance in strain SG-rev by
over-expression of wild type vraSR. The wild type form of
the vraSR genes linked to the promoter region of the vraSR operon
was fused to pGC2 and introduced into strain SG-rev. Over-
expression of the wild type form of vraSR in SG-rev caused full
recovery of VISA type vancomycin resistance: MIC was increased
from 1 to 3 mg/ml (Figure 5).
Table 2. Number of genes with significant transcriptional changes and respective functions in SG-R and SG-rev derived by
Microarrays analysis.
SG-R/SG-S SG-R/SG-rev
Functional Category
Total of genes with
altered transcription
Number of
genes Up-
regulated
Number of
genes Down-
regulated
Total of genes with
altered transcription
Number of
genes Up-
regulated
Number of
genes Down-
regulated
Ribosomal proteins: Synthesis and
modification
17 — 17 17 — 17
Protein synthesis: Translation factors,
and tRNA and rRNA base modification
3 — 3 3 — 3
Transport and binding proteins 20 8 12 18 6 12
Protein fate: protein and peptide
secretion and trafficking/degradation of
proteins, peptides, and glycopeptides
6 4 2 6 4 2
Post-translational modification, protein
turnover and chaperones
2 2 — 2 2 —
Amino acid transport and metabolism/
Amino acid biosynthesis
4 — 4 4 — 4
Energy metabolism 15 6 9 15 6 9
Pathogenesis 16 2 14 16 2 14
Regulatory functions 12 4 8 12 4 8
Cell envelope/Cell envelope biosynthesis 15 7 8 15 7 8
Biosynthesis of cofactors, prosthetic
groups, and carriers: Menaquinone
and ubiquinone
7 — 7 7 — 7
Inorganic ion transport and metabolism 6 — 6 6 — 6
Central intermediary metabolism 7 1 6 7 1 6
Biosynthesis of secondary metabolites 2 1 1 2 1 1
Signal transduction 7 2 5 7 2 5
DNA metabolism: DNA replication,
recombination, and repair
4 1 3 4 1 3
Nucleotide transport and metabolism 2 — 2 2 — 2
Carbohydrate transport and metabolism 3 — 3 3 — 3
Fatty acid and phospholipid metabolism: 5 — 5 5 — 5
Detoxification 1 — 1 1 — 1
Drug resistance 2 1 1 2 1 1
Mobile and extrachromosomal element
functions: Prophage functions
1 1 — 1 1 —
Unknown function 82 25 57 81 25 56
Total of genes 239 65 174 236 63 173
doi:10.1371/journal.ppat.1002505.t002
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Table 3. Mutations identified by whole genome sequencing analysis of SG-S, SG-R, and SG-rev strains.
Locus (gene identification number)
Number of
mutation Mutation
Effect of
mutation USA300 TCH1516 N315 Other Function SG-S SG-R SG-rev
1 C27978RA27978 A165RD165 (non -
synonymous)
USA300HOU_0020 SA0019 yycH Membrane protein. Part
of the yycFG operon [14]
2 + +
2 G 737170RA737170 G551RE551 (non -
synonymous)
USA300HOU_0683 SA0617 vraG ABC - transporter
permease [16]
2 + +
3 G 1206012RT1206012 D109RY109 (non-
synonymous)
USA300HOU_1133 SA1039 lspA lipoprotein-specific type II
signal peptidase [32,70]
2 + +
4 T2027986RC2027986 Y220RC220 (non -
synonymous)
USA300HOU_1882 SA1702 yvqF Conserved hypothetical
protein. Part of the vraSR
operon [22]
2 + +
5 Deletion T2027914 Frameshift mutation.
Premature stop
codon at 234 aa
USA300HOU_1881 SA1701 vraS Two-component sensor
histidine kinase [21]
2 2 +
6 Deletion from
T1036471 to A1036838
Deletion 2888 pb at the 59 side – USA300HOU_0983
(com k – competence gene) 4409 pb at the 39
side – USA300HOU_0984 (glycosyltransferase
GT1_gtfA_homolog)
Intergenic region 2 + +
doi:10.1371/journal.ppat.1002505.t003
Figure 4. Loss of vancomycin resistance in strain SG-R complemented with the wild type yvqF gene. Vancomycin susceptibilities were
evaluated by the E-test and by population analysis – as described in the Methods.
doi:10.1371/journal.ppat.1002505.g004
Genetic Changes in Vancomycin Resistant S. aureus
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Role of yvqF in the transcription of vraSR: evidence for
yvqF as a negative regulator
In order to further explore the connection between yvqF and vraSR
at the transcriptional level, qRT-PCR was performed. The total
RNA from strains SG-S(pGC2::yvqFmut), SG-R(pGC2::yvqFwt) and
SG-rev(pGC2::vraSRwt) was converted into cDNA and the amount
of vraS cDNA expressed by each mutant was determined by qRT-
PCR. Strains SG-S, SG-R and SG-rev with the carrier plasmid
pGC2 were used as controls. As shown in Figure 6 transcription of
vraS was up-regulated in the resistant strain SG-R (five-fold
compared to the SG-S strain) and highly up-regulated in SG-
rev(pGC2::vraSRwt) (approximately 220 fold compared to the
parental vancomycin susceptible strain), i.e., in two strains that
carried a mutated form of YvqF. The huge increase of vraS transcript
in SG-rev(pGC2::vraSRwt) was presumably caused by the high copy
number of the plasmid carrying the vraS gene in addition to the
chromosomal copy of vraS.
Interestingly, SG-S(pGC2::yvqFmut) and SG-R(pGC2::yvqFwt)
that were both vancomycin susceptible and carried both wild type
and mutated forms of the yvqF gene exhibited the same level of vraS
transcription as the parental strain SG-S that carried the
chromosomal copy of wild type yvqF gene (see Figure 6). This
indicates that decrease of vraS transcription in SG-R(pGC2::yvqFwt)
is not due to the high copy number of the introduced plasmid that
carried the wild type yvqF gene but rather it was due to the
functional activity of wild type YvqF.
These observations identify the wild type form of YvqF as a
negative controller of vraSR preventing up-regulation of this
genetic system under normal conditions of growth. SG-rev
containing the mutated form of yvqF did not show over-expression
of vraS presumably due to the mutation in the vraS gene which
caused loss of the histidine kinase activity of VraS and shutdown of
the VraSR system.
Widespread role of YvqF in the control of gene
expression
Further evidence that YvqF is part of the regulatory circuits of S.
aureus was provided by additional qRT-PCR assays. Transcription
of prsA, sgtB, orf1 in the vraSR operon, and orf SA2221 - all
belonging to the VraSR regulon [21] – were over expressed in the
VISA strain SG-R, but the transcription of these four genes
became down-regulated in SG-R(pGC2::yvqFwt) (see Figure S2-A).
The same pattern was also evident for lytM that appears to be an
additional member of the VraSR regulon (data not shown).
Genes involved in different functional categories such as
transport and binding proteins (sptC), protein fate (sspB), fatty acid
and phospholipid metabolism (acpD), inorganic ion transport and
metabolism (sirA), detoxification (sodM), and energy metabolism
Figure 5. Recovery of vancomycin resistance in strain SG-rev complemented with the wild type vraSR genes. Vancomycin
susceptibilities were evaluated by the E-test and by population analysis – as described in the Methods.
doi:10.1371/journal.ppat.1002505.g005
Genetic Changes in Vancomycin Resistant S. aureus
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(lctE and narK) were found to be over-expressed in the VISA mutant
complemented with the wild type form of yvqF (see Figure S2-B).
Down-regulation of virulence related genes in the VISA
strain SG-R
Interestingly, a direct or indirect transcriptional connection
between yvqF and important virulence related genes such as agrA, rot,
sarH1, spa, alpha-hemolysin, etc, was also observed. All these genes
were down-regulated in the VISA strain SG-R when compared with
their transcription in the parental strain SG-S and their inhibition of
transcription was reversed in SG-R(pGC2::yvqFwt) in parallel with
the loss of resistance to vancomycin (see Figure 7).
Discussion
During the extensive three weeks long vancomycin chemother-
apy the invading USA300 strain SG-S acquired mutations in four
genes that were identified in the isogenic strain SG-R in the
determinants yvqF, yycH, vraG and lspA. An additional alteration
was also detected in the resistant bacterium in an intergenic
region.
Primary role of the yvqF mutation in the VISA type
resistance of strain SG-R
Gene yvqF is part of the VraSR operon [22] and it encodes for
a membrane protein the biological function of which is not fully
understood. Mutations in yvqF were found in several VISA strains
including strain JH2, one of the ‘‘early’’ VISA isolates in the JH
series of strains which belong to the MRSA clone ST-5 [7] and a
variety of other VISA isolates from diverse geographic sources
[7,17]. A single substitution of tyrosine to cysteine in the
intracellular domain of YvqF in SG-R caused over-expression of
the vraS transcript (see Figure 6) suggesting that the intact YvqF
acts as an inhibitor of VraS function and the mutation has
completely abolished this inhibitory function. One may speculate
that introduction of a cysteine residue may cause conformational
change of YvqF by forming intra or inter-molecular disulfide
bond. The results of the complementation experiments shown in
Figures 4 and 6 clearly identify the mutation in this gene as the
genetic change responsible for the increased vancomycin MIC
value of strain SG-R and also for the other pleiomorphic
alterations identified in the resistant bacterium (e.g., thick cell
wall, slow autolysis, abnormal cell separation, etc).
YvqF is a negative regulator of the vraSR operon
Besides identifying the mutation in yvqF as the genetic change
responsible for the increased vancomycin MIC value, the
complementation experiments also settle a more general issue
related to the functioning of the VraSR system. The role of YvqF
as a negative regulator was based until now on homology with
orthologs of this gene in other bacterial species. The S. aureus YvqF
shows amino acid similarity to LiaF of B. subtilis that was shown to
Figure 6. Transcription of vraS in strains SG-S, SG-R and SG-rev and their various genetic constructs. The expression of vraS mRNA was
determined by qRT-PCR. As internal control, the expression was also determined in each sample for the pta mRNA.
doi:10.1371/journal.ppat.1002505.g006
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be a potent negative regulator of the expression of LiaR which is
the ortholog of S. aureus VraR [23]. Deletion analysis of the
liaIHGFSR operon revealed that LiaF is an essential component of
the LiaRS signaling system for maintaining it in a repressed state.
Additional evidence for the role of LiaF as a negative controller of
LiaSR was also provided by studies in Streptococcus mutans and
Listeria monocytogenes [24–25].
The results of the complementation experiments described in this
communication together with the titration of the vraS transcript
provide a direct experimental evidence for the unequivocal
identification of YvqF as an inhibitor of VraS function in S. aureus
and this interpretation is in accord with the proposed role of YvqF in
other gram positive bacteria [23–25]. Evidence for a direct
interaction between YvqF and VraS was also supported by
McCallum et al. who used the bacterial two-hybrid system to
demonstrate such an interaction [26]. However, the findings with the
two-hybrid system were interpreted as evidence for a role of YvqF as
an activator – rather than as a repressor – of signal transduction.
Further experimental work will be needed to sort out these different
interpretations.
Gene yycH is part of an operon containing the structural
determinants of the two-component system WalKR (YycFG) that
controls part of the autolytic system of S. aureus and biofilm formation
as well [14–15]. It was shown that the YycI and YycH orthologs in B.
subtilis interact to negatively control the YycF activity [27].
Substitution of alanine to aspartic acid in the YycH protein of strain
SG-R appears to be in the extracellular domain of the protein. The
mutation may affect the inhibitory activity of YycH on the YycG
sensor domain. It was previously reported that integration of an IS256
in the promoter region of the yycFGHI operon led to over-expression
of the yycFGHI genes and VISA type vancomycin resistance in a
clinical isolate recovered from a tracheal secretion [28–29].
Figure 7. Transcription of virulence related genes in strains SG-S(pGC2), SG-R(pGC2) and SG-R(pGC2::yvqF wt). The expression of each
mRNA was determined by qRT-PCR. As internal control, the expression was also determined in each sample for the pta mRNA. orf SA1007 encodes for
alpha-hemolysin, and orf SA1813 encodes for an hypothetical protein, similar to leukocidin chain LukM.
doi:10.1371/journal.ppat.1002505.g007
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Whether or not the mutation in the yycH gene identified in
strain SG-R contributes to the phenotype of this VISA strain is
unclear. The slight difference in autolytic rate observed between
SG-S and SG-rev (see arrow in Figure 3) and the minor
compositional abnormality detected in the SG-R peptidoglycan
(slight decrease in the representation of muropeptide 1) may
represent consequences of this mutation in the WalKR system
[14].
Gene vraG encodes an ABC transporter permease which is
part of an ATP-binding cassette the expression of which is
controlled by yet another two-component regulatory system
GraSR [16]. GraSR was shown to be a major contributor to the
VISA type resistance in some clonal types of S. aureus [30–31].
Deletion of vraG in the VISA strain Mu50 caused hypersensitivity
to vancomycin [16]. The recently sequenced JH9 clinical isolate
was also shown to carry a truncated YycH protein and an amino
acid substitution in VraG [7]. It was proposed that the VraFG
ABC transporter may enhance export of cell wall/teichoic acid
precursors [16]. The particular point mutation in vraG of strain
SG-R may or may not contribute to the phenotype of the resistant
strain. However, the transcript of vraG remains highly expressed in
both SG-R and SG-rev indicating that transcription of this gene is
not under the control of VraSR system.
Gene lspA – a lipoprotein-specific type II signal peptidase –
has not been seen in mutated form in other VISA isolates. The
lspA gene was shown to be a virulence factor in S. aureus [18]. The
mutation of aspartic acid to tyrosine identified in strain SG-R
should cause loss of catalytic activity of this protein since the
aspartic acid residue is one of two catalytic amino acids in the
active site [32]. The mutation in lspA should cause loss or decrease
of virulence in strain SG-R.
Intergenic region Sau-02 – a small non-protein-coding
RNA – was first described in a study focusing on the identification
of sRNAs that were differentially expressed in small colony
variants (SCVs) of S. aureus. In SCVs Sau-02 was found to be down-
regulated in the stationary phase of growth [19] and it was
suggested that small regulatory RNAs may play a role in the
control of growth phase in SCVs of S. aureus. Deletion of Sau-02
from the SG-R chromosome could be a possible contributor to the
aberrant growth pattern identified in strain SG-R.
Genetic mechanism of the loss of antibiotic resistance in
the revertant strain SG-rev
The USA300 VISA strain SG-R was shown to be unstable in
the absence of drug selection and the revertant strain SG-rev has
almost fully recovered (except for 8 genes) the transcriptional
pattern of the parental strain. In addition – in SG-rev – each of the
abnormalities observed in the VISA strain such as slow autolysis
and abnormalities of cell wall structure – have returned to the
normal properties characteristic of the parental strain. The
antibiotic MIC values of the revertant isolate have also decreased
‘‘back’’ to the MIC values of the parental strain SG-S or even
slightly below those values.
Full genome sequencing of the revertant strain showed that
these bacteria have retained each of the five genetic alterations
identified in the resistant strain but gained a single additional
frameshift mutation in vraS which appears to be responsible for
reversion of all the phenotypic and transcriptional changes
detected in the resistant isolate.
The single nucleotide deletion in the vraS gene should lead to the
production of a truncated histidine kinase VraS. The two-
component system VraSR is a key regulator of the cell wall
stimulon of S. aureus and it seems to act as a sentinel, sensing
perturbations in cell wall synthesis and activating the transcription
of several genes to preserve and repair the compromised cell wall
[21,33]. It was previously shown that in mutants with inactivated
vraSR the level of vancomycin and oxacillin resistance was reduced
[21,34]. Moreover, mutations in vraSRwere also identified in several
clinical VISA isolates [7,35,36]. Most interestingly, the same VraS
mutation detected in the SG-rev strain was also identified in a
recently identified revertant strain JH9rev (manuscript in prepara-
tion) and in a susceptible derivative of the VISA strain MU50 [30].
These observations strongly suggest that in several S. aureus lineages,
a common mechanism leading to the loss of vancomycin resistance
involves a mutation in the vraS gene. Such a hypothesis is
corroborated by the results of the complementation experiment:
the construct SG-rev(pGC2::vraSRwt) showed full recovery of
vancomycin resistance and over-expression of vraSR (Figures 5
and 6).
The powerful impact of vraS mutation on the transcription of a
wide range of genetic determinants is indicated by the finding that
in the revertant strain SG-rev the great majority of the 239 genes
which were shown to have altered transcription in the resistant
mutant SG-R returned to the normal pattern of transcription as
seen in the parental strain SG-S.
Altered transcription of genes in the antibiotic resistant
VISA isolate SG-R
In total, 239 genes showed altered transcription in the resistant
strain compared to the parental strain SG-S. All but eight of these
transcriptional changes were fully reversed in the revertant strain
SG-rev. The genes with altered transcription included signal
transduction and regulatory functions.
Out of the 191 genes whose expression is commonly altered
when S. aureus is challenged with inhibitory concentrations of cell
wall inhibitors [33], 50 genetic determinants involved in cell wall
metabolism (murZ, sgtB), stress responses (msr, htrA, and psrA) and
other cellular functions were found to be differentially transcribed
in the resistant mutant. Among these 50 genes, 29 were previously
classified as members of the cell wall stimulon of S. aureus [33].
Interestingly, 17 genes involved in the synthesis and modifica-
tion of ribosomal proteins and 2 translation initiation factors were
also down-regulated in the resistant strain. One can speculate that
a delay in the translation process may be a strategy used by the
resistant bacteria to compensate their imbalanced metabolic state
due to the significant alterations in gene transcription.
It is noteworthy that 28 of the 46 members of the VraSR
regulon [21], including the vraSR operon (orf1, yvqF, vraS and vraR),
were found up-regulated in the resistant strain SG-R. Among all
the transcriptional studies carried out with several different VISA
isolates [20,37–41], the transcriptional profile of SG-R resembled
most closely that of the VISA isolate JH9 which also carries a
mutation in the yvqF gene and exhibits over-expression of the
VraSR operon and regulon [7,39] (see Table S1).
Down-regulation of virulence-related genes in the VISA
isolate SG-R: a ‘‘stealth’’ strategy of invasion?
The vancomycin susceptible parental isolate SG-S belongs to
the USA300 clonal lineage which has an exceptionally high
potential to cause disease, due mainly to a high expression and
activity of virulence determinants such as the quorum sensing
regulator agr, phenol-soluble modulins (PMS), alpha-toxin and
PVL [42–47]. Surprisingly, all these virulence factors with the
exception of pvl were down-regulated in the resistant strain.
Reduced transcription of the global virulence regulators agr [48],
rot [49], sarH1 [50] as well as srrAB (also involved in the regulation
of energy metabolism) [51], and the genetic determinants hld and
Genetic Changes in Vancomycin Resistant S. aureus
PLoS Pathogens | www.plospathogens.org 11 February 2012 | Volume 8 | Issue 2 | e1002505
spa was also observed in strain SG-R. These findings are consistent
with results of other studies with different VISA isolates:
acquisition of VISA type resistance seems to be accompanied by
attenuation of virulence expression [9,38,39,52].
The prolonged course of disease, frequent treatment failure
inspite of extensive antibiotic therapy and frequent relapse
observed in most cases of infections with VISA type S. aureus are
not likely to be simply related to the modestly increased MIC
values in the resistant isolates recovered from patients. In
wondering about how genetic/biochemical changes detected in
VISA type isolates may contribute to these unique clinical features
of S. aureus infections, it is conceivable that the massive down-
regulation of important staphylococcal virulence genes – rather
than the modestly increased MIC value – may be the key
contributing factor.
Such a decrease in virulence appears to be a direct consequence
of the mode of action of vancomycin. In this scenario, vancomycin
‘‘traps’’ the peptidoglycan precursor Lipid II which triggers one of
the two-component sensory regulatory systems ‘‘assigned’’ to
monitor the status of cell wall biosynthesis in the bacteria. Turning
on one or the other of these regulatory systems (such as VraSR,
WalKR or GraSR) initiates a cascade of transcriptional events that
involve not only cell wall related determinants but also
transcription of major virulence genes. Consistent with this model,
a reversible down-regulation of virulence genes such as spa, rot,
sarH1 was already described when the vancomycin susceptible
strain JH1 was briefly exposed to vancomycin at the MIC value of
the isogenic VISA isolate JH9 [39]. In VISA strains such initially
reversible down regulation in virulence will become permanent by
the appearance of mutations in a relevant genetic determinant
such as yvqF in the case of the VISA isolate SG-R. Decreased
virulence of VISA strains is consistent with observations made in
clinical cases of such infections [53–56] and was also documented
in the rat model [57] and Galleria mellomella models [52] of
staphylococcal disease.
Our data suggest that VISA strains may employ a ‘‘stealth’’
strategy for invasion of the host. Down-regulation of major
virulence determinants such as agr, rot, sasH1, spa and others
together with the inactivation of an important virulence gene lspA
detected in the SG-R isolate may allow invading bacteria that seed
deep tissues to escape detection by the innate immune system and
to persist in body sites such as a damaged heart valve, prosthetic
devices or bone tissue where immune surveillance is poor or
otherwise compromised.
Materials and Methods
Ethics statement
The strains used in this study originated from the University of
California San Francisco. The following is their policy on IRB
approval. Research on Specimens and Data That Does Not
Require CHR Review. The Committee on Human Research
(CHR) at UCSF is charged with reviewing all research that
involves human subjects http://www.research.ucsf.edu/chr/
about/chrProgDesc.asp. However, some research involving only
unidentifiable or coded private information or specimens does not
qualify as human subjects research and does not require CHR
review.
Since the strains were de-identified and analyzed anonymously
and the strains, not a human, were studied, this is exempt from
human research committee approval.
Preliminary characterization of these isolates was done as
described in reference number 11 of this manuscript.
Strains
A vancomycin susceptible S. aureus isolate (vancomycin MIC:
1.5 mg/ml) belonging to the USA300 genetic background was
recovered in November 2005 from the blood culture of a 59-year-
old male patient admitted to San Francisco General Hospital. This
isolate will be referred to as SG-S (for San Francisco General
Hospital-Susceptible) throughout the paper. A second isolate of the
same clonal type but expressing intermediate resistance to
vancomycin (MIC: 3 mg/ml) – named SG-R (for San Francisco
General Hospital-Resistant) was recovered from a bone biopsy
specimen of the same patient after a 6 week course of vancomycin
therapy. Detailed clinical history of the patient and preliminary
characterization of the isolates were described recently [11]. A
laboratory derived revertant named SG-rev (vancomycin MIC:
1 mg/ml) was obtained by serial passage of SG-R in tryptic soy
broth for 15 days in the absence of vancomycin.
USA300 isolates carrying the multicopied carrier plasmid pGC2
[58] were labelled SG-S(pGC2), SG-R(pGC2) and SG-rev(pGC2).
Isolates carrying wild type form of yvqF or the mutated form of this
gene were labeled SG-R(pGC2::yvqFwt) or SG-S(pGC2::yvqFmut)
respectively. Mutants carrying the multicopy plasmid pGC2
containing the wild type vraSR genes linked to the vraSR operon
main promoter region were referred to as SG-rev(pGC2::vraSRwt).
Growth conditions
S. aureus strains were grown in tryptic soy broth (TSB) (Difco
Laboratories) with aeration at 37uC, on tryptic soy agar plates
(TSA) (Difco Laboratories) or on brain heart infusion agar (Difco
Laboratories) at 37uC. Escherichia coli strains were grown in Luria-
Bertani broth (Difco Laboratories) with aeration at 37uC.
Chloramphenicol, (20 mg/ml) and ampicillin (100 mg/ml) were
used as recommended by the manufacturer (Sigma) for the
selection and maintenance of S. aureus and E. coli transformants,
respectively.
DNA methods
DNA manipulations were performed by standard methods [59].
Restriction enzymes were used as recommended by the manufac-
turer (Invitrogen). Routine PCR amplification was performed with
AmpliTaq DNA Polymerase (Applied Biosystems) Wizard Plus
Minipreps and Midipreps purification systems (Promega) were
used for plasmid extraction. Ligation reactions were performed
using T4 Ligase (New England Biolabs). PCR products were
cleaned with a QIAquick PCR purification kit and sequenced.
Sequencing was performed at Genewiz, Inc, NJ.
Growth curves
Overnight cultures were diluted in 50 ml TSB to an OD620 of
0.02. Cultures were incubated with agitation at 37uC for 5 hours.
Increase in OD620 was measured every 30 minutes using a
Novaspec II Spectrophotometer (Pharmacia, LKB).
Triton X-100 stimulated autolysis
Cells were grown to mid-exponential phase, chilled in an ice-
ethanol bath, harvested, and washed with ice-cold water. Cells
were then suspended to an OD620 of 1.0 in lysis buffer (50 mM
glycine buffer, pH 8.0, containing 0.01% Triton X-100) as
previously described [60]. The rate of autolysis was measured at
37uC for 3 h every 15 minutes as a decrease of OD620.
Determination of antibiotic susceptibility
Antibiotic susceptibility level (MIC) to vancomycin, oxacillin,
daptomycin and fosfomycin were determined by the E-test
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following recommendations by the manufacturer (Ab Biodisk). A
more detailed evaluation of vancomycin and oxacillin susceptibil-
ity was done by population analysis. Linezolid and tigecycline
susceptibility were determined by the disk diffusion method
following recommendations by the manufacturer (Ab Biodisk).
Susceptibility to moenomycin was determined by tube dilution
as previously described [61].
Population analysis profiles
Population analysis profiles (PAPs) were performed as described
previously [62]. Overnight cultures were plated at various dilutions
(1021, 1022, 1023 and 1025/100, 1021, 1023 and 1025) on TSA
plates containing a series of concentrations of vancomycin (Sigma)
or oxacillin (Sigma) and bacterial colonies were counted after
incubation of the plates at 37uC for 48 h.
Analysis of peptidoglycan composition
Cell walls were isolated from exponential phase cells, peptido-
glycan purified and hydrolyzed with the M1 muramidase and the
resulting muropeptides reduced with borohydride and separated
by reverse-phase high-performance liquid chromatography (RP-
HPLC) – as previously described [13].
Transmission Electron Microscopy
One ml aliquots of bacterial cultures were harvested by low-
speed centrifugation and fixed with 1 ml of 2.5% (v/v)
glutaraldehyde. Electron microscopy was done at the Electron
Microscopy Service of The Rockefeller University. Electron
micrographs were selected after scanning numerous fields at low
power magnification to make sure that photos presented at high
power magnification represent ‘‘typical’’ structures.
Genomic sequence analysis
The genome sequencing was done at the Rockefeller Uni-
versity’s Genomics Resource Center using Illumina’s Genome
Analyzer IIx. Between 3 to 14 million 35 bp reads were generated
per isolate. Software, called IdentPoly, was developed in the lab to
process the reads, carry out a reference-based assembly, and detect
polymorphisms. The reads were trimmed and filtered based on
quality scores and then assembled onto the closely related finished
genomic sequence of the MRSA strain USA300_TCH1516 [63–
64]. For each isolate, a mean read coverage of 30–1506 was
achieved on the reference genome. While a small percentage,
,1%, of the reads from each isolate do not map to the reference,
these reads are the same amongst the isolates, so it is very likely
that these reads are from genomic islands present in the isolates
but not the reference.
Polymorphisms were detected using a variant of a Bayesian
probabilistic model that was previously described [7]. In contrast
to contemporary methods, this model allowed for the detection of
polymorphisms .5 bp. The model was rigorously tested on both
synthetic and real data harboring known substitutions, insertions,
deletions, inversions, etc. ranging from 1–10,000 bp in size.
Confirmation of genomic mutations
DNA fragments containing the mutations identified by whole
genome sequencing were amplified by PCR using the following
conditions: 94uC for 4 min; 30 cycles of 94uC for 30 s, 50uC for
30 s, and 72uC for 40 s; and one final extension step of 72uC for
5 min. The primers used for each PCR reaction are described in
Table S2. The purified PCR products were cleaned with a
QIAquick PCR purification kit and sequenced. Sequencing was
performed at Genewiz, Inc, NJ.
qRT-PCR
The levels of different mRNA transcripts were quantified in the
different strains by qRT-PCR. Total RNA was cleaned from DNA
contamination using the RNeasy Plus micro kit, which includes a
non enzymatic DNA removal step. RT- was performed by using
the AffinityScript (Stratagene) in a 20 ml reaction mixture under
the following conditions: 10 min at 65uC, 2 h at 42uC and 15 min
70uC by using random hexamers as primers. To quantify cDNA
generated by reverse transcription from target RNA, real time
PCR with SYBR Green I was performed by using SYBR Green
PCR master mix in an ABI Prism 7900 Sequence Detection
System (Applied Biosystems). The 10 ml reaction mixture con-
tained 16 iTaq SYBR Green PCR supermix with ROX (BioRad
laboratories), forward and reverse primers (each at a concentration
of 100 nM), and 5 ml of template (reverse transcription pro-
duct).The primers were designed by Oligo7 software (Applied
Biosystems) and are listed in Table S3. The thermal conditions
were: 2 min at 95uC and followed by 40 cycles at 95uC 15 sec,
55uC for 15 sec and 72uC 30 sec. Every sample was run in
triplicates. A threshold value for the fluorescence of all samples was
set manually. The reaction cycle at which the PCR product
exceeds this fluorescence threshold was identified as the threshold
cycle (CT). The CT was then converted to relative quantity of
mRNA by using a standard curve. The standard curve was
generated via the qRT-PCR program conditions using serial 2 fold
dilutions of genomic DNA. Relative gene expression was expressed
as a ratio of specific cDNAs concentration to housekeeping gene
(pta) concentration.
Microarrays
Ten micrograms of each RNA sample were reverse transcribed,
fragmented, and 39 biotinylated, following the manufacturer’s
recommendations for processing antisense prokaryotic arrays
(Affymetrix). A total of 1.5 mg of labeled material was then
hybridized to an S. aureus GeneChip, washed, stained, and scanned
as previously described [48,65]. In total, RNA from at least two
independent biological replicates was processed for each strain.
Data obtained from the scans of the microarrays were imported
into the Genespring software version GX 11.0 (Agilent). Data were
summarized with the GCRMA algorithm [66] and normalized to
the quantile in order to reduce chip to chip variation. Baseline
transformation was then performed to the mean of all chips. Gene
lists were derived with volcano plots, which are constructed using
fold change values and p-values. P-values were calculated by the
unpaired t–Test with no post hoc correction. Genes that showed a
fold change cut off $2 accompanied with a p-value cut off #0.05
in at least one of the comparisons were selected for further
investigation.
All experiments – including growth and autolysis curves,
population analysis profiles were repeated at least 2 times in
order to assure reproducibility.
Construction of pGC2::yvqFmut, pGC2::yvqFwt, and
pGC2::vraSRwt plasmids
A DNA fragment containing the main promoter region of the
vraSR operon (upstream from orf1 [22]) was amplified by PCR
using the Phusion High-Fidelity DNA polymerase (New England
Biolabs) and primers P_XbaI (59-AACCTCTAGATGCTCA-
AATTGAGCATACGG-39) and PvraSLower (59-AACTAT-
CACCTTTTATAATAAG-39). Primer P_XbaI was engineered
to carry an XbaI restriction site (underlined in the primer
sequence). The following PCR conditions were used: 98uC for
2 min; 25 cycles of 98uC for 10 s, 43uC for 30 s, and 72uC for
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20 s; and one final extension step of 72uC for 7 min. The purified
PCR product was cleaned, digested with XbaI (Invitrogen), and
phosphorylated with a T4 Polynucleotide Kinase (New England
Biolabs).
The wild type forms of yvqF/vraSR genes and the mutated form
of yvqF gene were amplified from the SG-S and SG-R
chromosomal DNAs, respectively, using the Phusion High-Fidelity
DNA polymerase (New England Biolabs) and primers
yvqF300UP (59-ATGACACACAAATATATATCAACGCAA-
ATG-39)/yvqF300Lower_HindIII (59-AACCAAGCTTTCATC-
GATAAATCACCTCTA-39) and VraSUP (59-ATGAACCACT-
ACATTAGAA CAATTGGTTCA-39)/VraRLower_HindIII (59
– CCCCAAGCTTCTATTGAATTAAATTATGTT-39), respec-
tively. Primers yvqF300Lower_HindIII and VraRLower_HindIII
were engineered to carry a HindIII restriction site (underlined in
the primer sequences). The following PCR conditions were used:
98uC for 2 min; 25 cycles of 98uC for 10 s, 43uC for 30 s, and
72uC for 30 s (amplification of the yvqF gene) and 98uC for 2 min;
25 cycles of 98uC for 10 s, 43uC for 30 s, and 72uC for 1 min
(amplification of the vraSR genes); and one final extension step of
72uC for 7 min. The purified PCR products were cleaned,
digested with HindIII (Invitrogen), fused separately with the vraSR
phosphorylated promoter region and linked to the pGC2 digested
with XbaI and HindIII. The ligation mixture was used to
transform E. coli DH5a (Invitrogen) competent cells to obtain
plasmids pGC2::yvqFmut, pGC2::yvqFwt, and pGC2::vraSRwt. The
correct sequences of the three constructs were confirmed.
Construction of SG-S, SG-R and SG-rev mutants
complemented with yvqFmut, yvqFwt, and vraSRwt
Plasmids pGC2::yvqFmut, pGC2::yvqFwt, and pGC2::vraSRwt
were introduced separately into S. aureus RN4220 electrocompe-
tent cells by electroporation with a Gene pulser apparatus (Biorad)
essentially as previously described [67]. The transformation
mixture was plated on TSA containing chloramphenicol (20 mg/
ml). Plasmids pGC2::yvqFmut, pGC2::yvqFwt, and pGC2::vraSRwt
were extracted and then electroporated separately into strains SG-
S, SG-R and SG-rev, respectively, as described previously [68].
The transformation mixture was plated on BHI containing
chloramphenicol (20 mg/ml) and two colonies resistant to
chloramphenicol from each different background were selected
for further assays.
Supporting Information
Figure S1 Heat map of differentially expressed genes in
SG-R compared to SG-S, SG-R compared to SG-rev, and
SG-rev compared to SG-S. *COL genome annotation.
(PDF)
Figure S2 Transcription of genes in strains SG-
S(pGC2), SG-R(pGC2) and SG-R(pGC2::yvqF wt). A.
Transcription of genes of the VraSR regulon. The
expression of each mRNA was determined by qRT-PCR. As
internal control, the expression was also determined in each
sample for the pta mRNA. Different assays provided evidence that
lytM is most probably an additional a member of the VraSR
regulon (data not shown). orf 2221 encodes for an hypothetical
protein. B. Transcription of genes with a variety of
metabolic functions. Transcription of lctE (energy metabolism),
acpD (fatty acid and phospholipid metabolism), sodM (detoxifica-
tion), sspB (protein fate), sirA (inorganic ion transport and
metabolism), narK (energy metabolism), and sptC (transport and
binding proteins) was compared in strains SG-S(pGC2), SG-
R(pGC2) and SG-R(pGC2::yvqF wt). The expression of each
mRNA was determined by qRT-PCR. As internal control, the
expression was also determined in each sample for the pta mRNA.
(PDF)
Table S1 Genes with significant expression changes in
SG-R compared to SG-S, and SG-R compared to SG-rev
and SG-rev compared with SG-S. The p-values that are not
listed are #0.05. Genes listed in bold were found up-regulated or
down-regulated in the VISA strain JH9 when compared with the
parental susceptible strain JH1 [1]; Genes identified with a star are
considered members of the VraSR regulon according to Kuroda
et al. [2]. (a) Genes with altered transcription when S. aureus is
treated with inhibitory concentrations of oxacillin, D-cycloserine
and bacitracin [3]. (b) members of the cell wall stimulon of S.aureus
[3]. SA – N315 genome ORF annotation; SACOL – COL
genome ORF annotation; SAUSA300 – USA300 genome ORF
annotation; SAV – MU50 genome ORF annotation. [1] McAleese
F, Wu SW, Sieradzki K, Dunman P, Murphy E, et al. (2006)
Overexpression of genes of the cell wall stimulon in clinical isolates
of Staphylococcus aureus exhibiting vancomycin-intermediate- S.
aureus-type resistance to vancomycin. J Bacteriol 188: 1120–
1133. [2] Kuroda M, Kuroda H, Oshima T, Takeuchi F, Mori H,
et al. (2003) Two-component system VraSR positively modulates
the regulation of cell-wall biosynthesis pathway in Staphylococcus
aureus. Mol Microbiol 49: 807-821. [3] Utaida S, Dunman PM,
Macapagal D, Murphy E, Projan SJ, et al. (2003) Genome-wide
transcriptional profiling of the response of Staphylococcus aureus to
cell-wall-active antibiotics reveals a cell-wall-stress stimulon.
Microbiology 149: 2719–2732.
(DOC)
Table S2 Primers used in sequencing.
(DOC)
Table S3 Primers used in the qRT-PCR studies.
(DOC)
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